Psoriasis: disease management with a brief review of new biologics.
Psoriasis is a chronic inflammatory dermatosis that affects 0.6% to 4.8% of the population and is seen in all ages. The disease is characterized by a well-demarcated, salmon-colored plaque surmounted by silver-white scales. Given the chronic nature of the disease, goal of treatment is to induce and maintain remission, with minimal short and long-term side effects from therapy. Most agents can be used alone or in combination with other treatment modalities.
SUNY Downstate Medical Center, Brooklyn, NY, USA.
Amor
A
Khachemoune
Sabrina
S
Guillen
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005544:Forecasting; D006801:Humans; D007155:Immunologic Factors; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D011701:PUVA Therapy; D011565:Psoriasis / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D012074:Remission Induction; D014467:Ultraviolet Therapy
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; C055085:calcipotriene; D002117:Calcitriol